Overview

Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial

Status:
Not yet recruiting

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

Safe Stop IPI-NIVO Trial: Early discontinuation of nivolumab upon achieving a (confirmed) complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab

Phase:

N/A

Details

Lead Sponsor:

Erasmus Medical Center

Treatments:

Nivolumab